EFFICACY OF KAGOCEL IN NONSPECIFIC PREVENTION OF ACUTE RESPIRATORY VIRAL INFECTIONS AND INFLUENZA

Acute respiratory viral infections (ARVI) are some of the most widely spread diseases worldwide that are of 80% of economic cost of infectious diseases. It is known that specific prophylaxis (vaccination) and, in some clinical cases, direct-acting antiviral prophylaxis are key strategies for the prevention of influenza as one of the most dangerous ARVI viruses. However, there are a number of reasons why specific prophylaxis of influenza does not entirely address the issue of prophylaxis of ARVI that are caused by more than 200 different viruses, such as formation of immune response only to vaccine influenza strains and absence of immune response to other respiratory infections, induction in the case of short-term protection, especially, in the aged and others. Prevention of influenza with antiviral drugs is limited by risks of development of resistant influenza strains aa well as contraindications and limitations of use. Therefore, the use of nonspecific drugs such as broad-spectrum antiviral drugs of interferon type (IFN) and their inducers (II), as well as sanitary and hygienic measures is recommended for prevention. For the purpose of prevention, the use of inducers of endogenic interferons is relevant in unvaccinated persons during pre-epidemic and epidemic ARVI periods; in high-risk group (students, medical professions, transport workers, elderly, patients with comorbid pathologies, people in structured organizations, for example, military personnel), in immunocompromised people. One of the most extensively studied interferon inducers widely used in clinical practice since 2003 for prevention and treatment of influenza and diseases caused by Herpesviruses is an antiviral drug Kagocel®. The paper presents real-time data of the preventive efficacy of Kagocel® in the therapy of acute respiratory viral infections and influenza caused by different viral strains including pandemic ones.

1. Zajcev A.A. Actual issues of epidemiology, pharmacotherapy and prevention of acute respiratory viral infections. Medical Review, 2018, No 11, рр. 53–57 (In Russ.)

2. Orlova N.V. Modern approaches to the treatment and prevention of acute respiratory viral infections. Medical alphabet, 2018, Vol. 2, No 21, рр. 29–34 (In Russ.)

3. On the state of the sanitary-epidemiological well-being of the population in the Russian Federation in 2018: State report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, 2019, 254 p. (In Russ.)

4. Iuliano A.D., Roguski K.M. , Chang H.H., Muscatello D.J., Palekar R., Tempia S., Cohen C., Gran J.M., Schanzer D., Cowling B.J., Wu P., Kyncl J., Ang L.W., Park M., Redlberger-Fritz M., Yu H., Espenhain L., Krishnan A., Emukule G., van Asten L., Pereira da Silva S., Aungkulanon S., Buchholz U., Widdowson M.A., Bresee J.S. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study // Lancet (London, England). 2018. Mar. Vol. 391, No. 10127. Р. 1285–1300.

5. Mortality by cause of death in 2018. Federal State Statistics Service. The form demo24 (In Russ.)

6. Legand A., Briand S., Shindo N., Brooks M.A., De Jong M.D., Farrar J., Aguilera X., Frederick G. Hayden Addressing the public health burden of respiratory viruses: the Battle against Respiratory Viruses (BRaVe) Initiative. Future Virol. Vol. 8, No. 10. Р. 953–968, Oct. 2013.

7. On the state of the sanitary-epidemiological well-being of the population in the Russian Federation in 2016: State report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, 2017, 220 р. (In Russ.)

8. On the state of the sanitary-epidemiological well-being of the population in the Russian Federation in 2017: State report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, 2018, 268 p. (In Russ.)

9. Sologub T.V., Tsvetkov V.V. Kagocel in the therapy of influenza and acute respiratory viral infections: Data analysis and systematization from the results of preclinical and clinical trials // Ter. Arkh. 2017. Vol. 89, No. 8. Р. 113.

10. Karetkina G.N. Influenza and other acute respiratory infections: modern principles and practice of treatment. Medical Council, 2017, No. 5, рр. 54–57 (In Russ.)

11. Maksakova V.L., Vasilieva I.A., Erofeeva M.K. The use of the drug «Kagocel» for the treatment and prevention of influenza and other acute respiratory viral infections. Medline Express, 2009, No. 1 (201), рр. 54–57 (In Russ.)

12. Petrov V.A., Rodionova N.V., Malyukov A.V., Nazarochkina O.V., Polezhaeva M.A., Razuvaev O.A. Clinical and epidemiological effectiveness of the late interferon inducer in the prevention of acute respiratory viral infections and influenza in the pre-epidemic period of 2017–2018. Attending doctor, 2018, No. 6, рр. 66–70 (In Russ.)

13. Tikhonova T.Yu., Kuzmina E.P., Kalinina Yu.S. Evaluation of the prophylactic effect of the late interferon inducer. Attending doctor, 2018, No. 10, рр. 28–31 (In Russ.)